- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04530851
Compare Outcome of Enhanced Recovery After Cesarean Surgery and Conventional Care
Compare Outcome of Enhanced Recovery After Cesarean Surgery and Conventional Care in Rajavithi Hospital
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research design is Randomized control trial. The pregnant women who go to elective cesarean section don't know the allocation. The group of ERAS protocol was separated from Conventional care in patient care unit.
The Pregnant are randomly in two group. In the ERAS group the pregnant receive the the intervention for preoperative care(Counselin, H2- antagonist and metroclopramide for prevent aspiration, Drink clear liquid until 2 hour before surgery), Intraoperative care (first generation cephalosporin in 60 minute before surgery, Clorhexidine for skin cleansing and Povidine for vaginal cleansing, regional anesthesia, keep warming, blunt expansion of uterine incision, do not peritoneal suture and subcuticular suture if less than 2 cm, local wound anesthesia.), post operative care ( Paracetamol and NSAIDs for for pain control, early remove catheter and ambulation, 5-HT3 antagonist for prevent nausea)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women who scheduled for elective Cesarean section at Rajavithi Hospital
Exclusion Criteria:
- Pregnant women who has preeclampsia with severe feature
- Pregnant women who has diabetes mellitus with uncontrolled blood sugar
- Pregnant women who has blood loss > 1,500 ml after surgery
- Pregnant women who has chrioamnionitis.
- Pregnant women who has severe medical disease
- Pregnant women who has BMI >= 40 kg/m2
- Pregnant women who has placenta adherence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Conventional care
This group is conventional care of pregnant women after Cesarean section
|
|
EXPERIMENTAL: ERAS protocol
This protocol for improve outcome of pregnant women after Cesarean section
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare length of stay of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
|
The primary outcome is length of stay (Day)
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare pain of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
|
The outcome is pain score (visual analogue scale )
|
1 year
|
Compare opioid use of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
|
The outcome are opioid use (Meperidine, Tramadol, Morphine)
|
1 year
|
Compare complication of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
|
The outcome are complication after surgery such as fever, wound infection, wound dehiscence, metritis
|
1 year
|
Compare bowel function of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
|
The outcome is time to passing gas after surgery(hour)
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 103/2562
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ERAS
-
Erasca, Inc.Active, not recruitingAdvanced or Metastatic Solid TumorsUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitation
-
University of ThessalyRecruiting
-
Yan FuxiaNot yet recruitingCardiac Surgery | Enhanced Recovery After SurgeryChina
-
Feng JiexiongCompleted
-
Stanley Dudrick's Memorial HospitalCompleted
-
The First Hospital of Jilin UniversityUnknownGastrostomy ComplicationsChina
-
University of CalgaryCanadian Foundation for Dietetic Research (CFDR)CompletedSurgery | Colorectal Disorders
-
Erasca, Inc.WithdrawnAcute Myeloid LeukemiaUnited States
-
Zuyderland Medisch CentrumCompletedColorectal Cancer | Enhanced Recovery After SurgeryNetherlands